Cutting Edge Science

The latest articles on RSV, invasive meningococcal disease and other conditions relevant to South African practice.

Sort by

Filters

Reset

Therapeutical Area
- Dermatology
- Diabetes
- Immunology
- Thrombosis
- Vaccines

A Practical Approach to the initiation, titration & intensification of injectables in Type 2 Diabetes - Dr. Angela Murphy

A Small Threat With A Big Impact: Understanding Meningococcal Disease in South Africa

Advancing Therapy in Type 2 Diabetes: The Soli-D Trial

Age and Serogroup Patterns: IMD in South Africa

Comprehensive analysis of Invasive Meningococcal Disease (IMD) patterns in South Africa, featuring GERMS-SA surveillance data from 2018-2024. Highlights age-specific incidence rates, with detailed focus on infant vulnerability (1.6 per 100,000) and adolescent/young adult peaks. Includes serogroup distribution trends across the country.

Age-Related Risk Factors for IMD: From Infants to Elderly

Comprehensive overview of age-specific risk factors for Invasive Meningococcal Disease (IMD), detailing vulnerability patterns across different life stages. Features specific risks for infants, adolescents, and elderly populations, including the impact of maternal antibody decline, nasopharyngeal colonization, and immunosenescence in older adults.

Valproate Risk Minimization Material - Patient Card

Basic Overview of Bone Disease in Gaucher

A Basic Overview with Prof Escobar (Interview)

Beyond Survival: Why Does IMD Rank as a High-Impact, Low-Incidence Threat Among Other Vaccine-Preventable Diseases?"

Comprehensive analysis of Invasive Meningococcal Disease (IMD) outcomes, featuring detailed mortality rates by serogroup and age group, with focus on the 20% survivor sequelae rate. Includes comparative analysis with other vaccine-preventable diseases (VPDs) and highlights the critical 24-hour window for treatment intervention.

Clinical Guidance for HCPs

Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics

Conjugate vs. Polysaccharide: The Science Behind Better Meningococcal Protection

Comprehensive comparison between meningococcal conjugate and polysaccharide vaccines, highlighting the immunological advantages of conjugate vaccines including long-duration antibody response, memory B cell production, and herd immunity benefits. Essential information for healthcare providers, immunization specialists, and public health officials seeking evidence-based vaccine selection guidance.

DELIVER-G: Real-World evidence of treatment Intensification in people with type 2 diabetes inadequately controlled on GLP-1 Receptor Agonists - Professor Timothy Bailey.

This section features recently published articles covering clinical developments across multiple therapeutic areas relevant to South African practice. Topics may include disease burden updates, diagnostic advances and treatment considerations across conditions such as RSV and meningococcal disease. Content is curated to reflect current relevance rather than being organised strictly by therapeutic area. New articles are added on an ongoing basis.

New articles are added periodically as relevant clinical publications and developments become available. The hub is designed to give healthcare professionals a single destination for staying current without needing to search multiple sources. Older articles remain accessible in the archive for reference. Update frequency may vary depending on the pace of relevant clinical developments.

Yes, articles are typically organised so that healthcare professionals can identify content relevant to their specific clinical interest or specialty. This structure supports efficient navigation for clinicians with limited time to browse extensive content libraries. Related articles on similar topics may also be highlighted for further reading. Full access to article content requires registration as a healthcare professional.

Latest Scientific Articles Across Therapeutic Areas

Filters

Therapeutical Area

A Practical Approach to the initiation, titration & intensification of injectables in Type 2 Diabetes - Dr. Angela Murphy

A Small Threat With A Big Impact: Understanding Meningococcal Disease in South Africa

Advancing Therapy in Type 2 Diabetes: The Soli-D Trial

Age and Serogroup Patterns: IMD in South Africa

Age-Related Risk Factors for IMD: From Infants to Elderly

Valproate Risk Minimization Material - Patient Card

Basic Overview of Bone Disease in Gaucher

Beyond Survival: Why Does IMD Rank as a High-Impact, Low-Incidence Threat Among Other Vaccine-Preventable Diseases?"

Clinical Guidance for HCPs

Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics

Conjugate vs. Polysaccharide: The Science Behind Better Meningococcal Protection

DELIVER-G: Real-World evidence of treatment Intensification in people with type 2 diabetes inadequately controlled on GLP-1 Receptor Agonists - Professor Timothy Bailey.

Confirm that you are a healthcare professional to continue reading.

Login For Healthcare Professionals

HCP Verification Required

RESEND SUCCESS

Verify Email Required

Restricted Content

Create an account

Welcome to Campus Sanofi

Success!

Welcome to Sanofi Campus

Latest Scientific Articles Across Therapeutic Areas

Filters

Therapeutical Area

A Practical Approach to the initiation, titration & intensification of injectables in Type 2 Diabetes - Dr. Angela Murphy

A Small Threat With A Big Impact: Understanding Meningococcal Disease in South Africa

Advancing Therapy in Type 2 Diabetes: The Soli-D Trial

Age and Serogroup Patterns: IMD in South Africa

Age-Related Risk Factors for IMD: From Infants to Elderly

Valproate Risk Minimization Material - Patient Card

Basic Overview of Bone Disease in Gaucher

Beyond Survival: Why Does IMD Rank as a High-Impact, Low-Incidence Threat Among Other Vaccine-Preventable Diseases?"

Clinical Guidance for HCPs

Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics

Conjugate vs. Polysaccharide: The Science Behind Better Meningococcal Protection

DELIVER-G: Real-World evidence of treatment Intensification in people with type 2 diabetes inadequately controlled on GLP-1 Receptor Agonists - Professor Timothy Bailey.

What kind of content is featured in this latest science section?

How frequently is new content added to this science hub?

Can healthcare professionals filter articles by specific topic of interest?

Confirm that you are a healthcare professional to continue reading.